BCR-ABL激酶区突变在酪氨酸激酶抑制剂耐药慢性髓性白血病患者中的分布及其影响因素

OBJECTIVE: To explore BCR-ABL kinase domain mutation profiles and clinical variables associated with them in tyrosine kinase inhibitor (TKI)-resistant patients with chronic myeloid leukemia (CML). METHODS: Imatinib-, nilotinib-, and/or dasatinib-resistant patients with CML who screened BCR-ABL mutat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Zhonghua Xue Ye Xue Za Zhi
Formato: Artigo
Idioma:Inglês
Publicado: Editorial office of Chinese Journal of Hematology 2020
Assuntos:
论著
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378281/
https://ncbi.nlm.nih.gov/pubmed/32654459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.06.006
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares